NorthShore University HealthSystem (NorthShore) has joined physIQ’s NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker. NorthShore will serve as an enrollment center and key partner in the Phase II validation stage of this study.

“Continuing NorthShore University HealthSystem’s mission to be at the forefront of innovation, we are thrilled to partner with physIQ again,” said Nirav S. Shah, MD, MPH, Medical Director of Quality Innovation and Clinical Practice Analytics, and Program Director of Outcomes Research for Quality and Transformation at NorthShore. “Using continuous multi-parameter vital signs and physiological features, we hope to support physIQ in establishing a targeted COVID-19 digital biomarker to help detect worsening patients.”

The DeCODe project is conducted in collaboration with the University of Illinois Hospital and Health Sciences System (UI Health). The objective of the study is to develop an early warning system potentially giving clinical teams more time to act on the warning signs of a person getting sick from COVID-19. Rather than relying on periodic point measurements, such as temperature and pulse oximetry, continuous multi-parameter vital signs and physiological features will be monitored remotely in the patient’s home during activities of daily living.

To support the Phase II enrollment goal of 1200 patients, NorthShore will enroll participants who are confirmed COVID-19 positive and recovering at home to evaluate the ability for the digital biomarker to detect and predict decompensation severity remote from the hospital.

“Adding NorthShore as a site brings new dimension to the study that will be extremely valuable to the study outcomes. Their established expertise in this area is an incredible asset to the DeCODe Study,” said Karen Larimer PhD, ACNP-BC, study PI and physIQ’s Director of Clinical Development.

Source: Company Press Release